TECARTUS

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, UK.

Active ingredients

The drug TECARTUS contains one active pharmaceutical ingredient (API):

1	Brexucabtagene autoleucel UNII 4MD2J2T8SJ - BREXUCABTAGENE AUTOLEUCEL
	Brexucabtagene autoleucel, a CD19-directed genetically modified autologous T-cell immunotherapy, binds to CD19 expressing cancer cells and normal B cells. Following anti-CD19 CAR T-cell engagement with CD19 expressing target cells, the CD28 co-stimulatory domain and CD3-zeta signalling domain activate downstream signalling cascades that lead to T-cell activation, proliferation, acquisition of effector functions and secretion of inflammatory cytokines and chemokines. This sequence of events leads to killing of CD19-expressing cells.
	Read more about Brexucabtagene autoleucel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TECARTUS Dispersion for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XL06		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XL Antineoplastic cell and gene therapy
Discover more medicines within L01XL06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02516667
EE	Ravimiamet	1835074
FR	Base de données publique des médicaments	60862404
GB	Medicines & Healthcare Products Regulatory Agency	393584
IL	מִשְׂרַד הַבְּרִיאוּת	8804
IT	Agenzia del Farmaco	049148012
LT	Valstybinė vaistų kontrolės tarnyba	1091697
PL	Rejestru Produktów Leczniczych	100446081
US	FDA, National Drug Code	71287-219, 71287-220